Pentosan Polysulfate (PPS)

What it is

A semi-synthetic sulfated polysaccharide (not a peptide) derived from beechwood hemicellulose, with a molecular weight of approximately 5,700 Da. PPS is FDA-approved as Elmiron for interstitial cystitis but is widely discussed in peptide and biohacking communities for its studied chondroprotective and anti-inflammatory properties when administered via injection for joint health. It acts as a glycosaminoglycan analog that has been studied for its ability to stimulate chondrocyte proteoglycan synthesis, promote hyaluronic acid production by synovial fibroblasts, and inhibit catabolic enzymes including MMPs, aggrecanase-1, hyaluronidase, and cathepsins. Long-term oral use has been associated with pigmentary maculopathy, a progressive retinal condition; this risk has not been observed with short-course injectable protocols, though long-term injectable safety data is limited. Note: included in this library because it is frequently discussed alongside peptides in joint health contexts, despite being a polysaccharide rather than a peptide.

Community-reported ranges

Dosing ranges sourced from published clinical trial protocols, community forums, and clinician-reported injectable protocols. Maculopathy data from peer-reviewed ophthalmology literature. Not dosing guidance.

Frequently discussed alongside

Based on community forum discussions. Not a recommendation to combine compounds.

Published research

PPS has been studied in multiple human clinical trials for knee osteoarthritis. A randomized double-blind placebo-controlled pilot study (Ghosh et al., 2005) examined intramuscular PPS at 3 mg/kg weekly for 4 weeks. An open-label trial (Kumagai et al., 2010) of 6 weekly subcutaneous injections at 2 mg/kg in 20 patients with mild knee OA reported significant pain and range-of-motion improvement maintained at 1 year. A Phase II RCT protocol (MaRVeL trial, 2024) is investigating oral PPS for knee OA with dyslipidemia. Preclinical studies have examined PPS interactions with cartilage matrix proteins and synovial fibroblasts. The pigmentary maculopathy risk was first described by Pearce et al. (2018) and has been confirmed in multiple subsequent studies, with prevalence and dose-response data published through 2025. Community-reported injectable dosing ranges are extrapolated from clinical trial protocols and are not standardized.

Reported side effects

From community self-reports. Not from controlled studies.

Long-term oral use has been associated with pigmentary maculopathy in an estimated 16–20% of chronic users, with strong cumulative dose dependency (most cases after 3+ years of daily oral use). No maculopathy cases have been reported with short-course injectable protocols, though long-term data is absent. Other reported effects include weak anticoagulant activity, alopecia (most common non-retinal side effect), GI disturbance, and transient liver enzyme elevation. Community users of injectable protocols have reported injection site soreness and occasional mild bruising.

Regulatory status